Anti-Human CD2 - DyLight® 488

Leinco Technologies
Product Code: LEI-C1831
Product Group: Primary Antibodies
CodeSizePrice
LEI-C1831-50ug50 ug£159.00
Quantity:
LEI-C1831-100ug100 ug£211.00
Quantity:
LEI-C1831-200ug200 ug£291.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: IgG2a
Antibody Clonality: Monoclonal
Antibody Clone: G11
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Shipping:
2-8°C
Storage:
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.

Further Information

Antigen Distribution:
CD2 is present on normal peripheral blood lymphocytes, thymocytes, mature circulating T-cells and a subset of NK cells.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 488
Format:
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Purified Recombinant Human CD2 (>98%)
Long Description:
CD2 is a 45-59 kD type I transmembrane glycoprotein belonging to the Ig superfamily. CD2 is the receptor for LFA-3/CD58. CD2 serves as an adhesion receptor that binds to CD58; generating the activation of CD2-positive T cells and NK cells and in the regulation of their cytolytic activities. CD2 is a specific marker for T cells and NK cells. Hence, it can be used in immunohistochemistry to identify the occurrence of these cells in tissue sections. The vast majority of T cell lymphomas and leukemias express CD2 which makes it possible to distinguish these conditions from B-cell lymphomas.
NCBI Gene:
914
Target:
CD2

References

1. Meuer, S.C. et al. (1984) Cell 36:897 2. Peterson, A. and Sneed, B. (1987) Nature 329:842 3. Bierer, B.E. et al.(1989) Annu. Rev Immunol. 7:579 4. Krensky, C.F. et al. (1982) Proc. Natl. Acad. Sci. USA 79:7489 5. Krensky, C.F. et al. (1983) J. Immunol. 131:611